Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risuteganib + sodium hyaluronate
- Development stage
- Unknown
- Lead developer
- Allegro Ophthalmics
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Peptides, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Topical, Ophthalmic
01
Overview
ALG-1007 is a fixed-combination topical ophthalmic drug candidate composed of 0.6% risuteganib and 0.125% sodium hyaluronate, developed for the treatment of dry eye disease (DED). It acts as an integrin inhibitor, targeting pathways involved in ocular surface inflammation and oxidative stress. Clinical trials have shown that ALG-1007 significantly improves signs and symptoms of dry eye compared to control arms, with a rapid onset of action and no reported drug-related adverse events or ocular irritation. The drug is being developed by Allegro Ophthalmics and has reached Phase II clinical development in the United States[3][4][5][8].
- Other names
- ALG 1007ALG1007ALG-1007
02
Targets
ITGA5:ITGB1 (Integrin α5β1)ITGA2/ITGB1 (Integrin alpha-2/beta-1 receptor)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)
Beyond the preview
Go deeper on risuteganib + sodium hyaluronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risuteganib + sodium hyaluronate.